Clinical Neuroscience Division
Advancing therapeutic interventions for neurodegenerative, psychiatric, and neurological disorders through AI-augmented diagnostics, novel drug discovery, and next-generation neurotechnology.
Clinical Trial Pipeline
Real-time status of our therapeutic candidates across multiple neurological and psychiatric indications.
Dual Kinase Inhibitor for Early-Stage Alzheimer's
Indication: Mild Cognitive Impairment & Early Alzheimer's Disease
Rapid-Acting Glutamatergic Modulator for MDD
Indication: Treatment-Resistant Major Depressive Disorder
Non-Invasive BCI for Locked-In Syndrome Rehabilitation
Indication: Severe Motor Neuron Disease & Brainstem Stroke
Lysosomal Clearance Enhancer for Parkinson's
Indication: Early Parkinson's Disease (Huntingtin Q75+/− models)
Neurotech & AI-Driven Diagnostics
Our clinical neuroscience pipeline is accelerated by proprietary neuroimaging AI, multi-omics biomarker panels, and closed-loop neurostimulation platforms. We integrate real-world data with longitudinal trial endpoints to identify responders earlier and reduce development timelines.
Global Clinical Network
Strategic partnerships with leading academic medical centers, specialty clinics, and independent research institutions.
Recent Publications & Data Readouts
Peer-reviewed findings, conference presentations, and regulatory milestones from our neuroscience teams.
Multi-modal AI prediction of treatment response in late-stage Alzheimer's clinical trials
Access Publication →Phase II results of AZN-918: Rapid symptom reduction in TRD without dissociative side effects
Access Publication →Closed-loop DBS optimization using real-time biomarker feedback in Parkinson's disease
Access Publication →Partner With Our Neuroscience Division
Whether you're a clinical site, academic researcher, or biotech innovator, we're expanding our trial network and technology partnerships globally.